MJH Life Sciences Celebrates Acquisition of Revolutionizing Atopic Dermatitis (RAD) Annual Meeting

Credit: MJH Life Sciences

MJH Life Sciences, the parent company of HCPLive, has announced the acquisition of the Revolutionizing Atopic Dermatitis (RAD) Annual Meeting, a premier CME-certified conference renowned for advancing knowledge in dermatology through the discussion of cutting-edge research.

With the acquisition, the RAD Annual Meeting will be integrated as a CME-certified conference within the Physicians’ Education Resource®, LLC legacy meeting portfolio and supported by the MJH Life Sciences' extensive dermatology brands, including HCPLive and Dermatology Times.

The acquisition comes as the field of dermatology finds itself amidst a revolution in the management of atopic dermatitis. Beginning in 2017, when the US Food and Drug Administration's approval of dupilumab (Dupixent) ushered in the age of biologics in atopic dermatitis, dermatologists have welcomed several landmark approvals in the last decade. This includes approvals for nonsteroidal topical options in ruxolitinib cream (Opzelura) and roflumilast cream (Zoryve) in 2021 and 2024, respectively.

Chaired by Jonathan Silverberg, MD, PhD, professor of dermatology and director of clinical research at the George Washington University School of Medicine and Health Science, the RAD Annual Meeting is known for its unique approach to dermatology education, including focused congresses in atopic dermatitis, alopecia areata, vitiligo, and eczema.

The RAD 2024 Annual Meeting, which was hosted as a collaborative meeting of 3 distinct congresses known as Revolutionizing Alopecia Areata, Vitiligo, and Eczema, was held in Chicago, Illinois from June 8 – 10, 2024. At RAD 2024, which was the 6th time the meeting has been held, the program featured dozens of sessions highlighting perspectives from leading subject experts in the field of dermatology, including Brett King, MD, PhD, Amy Paller, MD, Robert Bissonnette, MD, Raj Chovatiya, MD, PhD, and others.

At the RAD 2024 meeting, the community welcomed the presentation of LEVEL UP data, the Measure Up program, and the DELTA studies. Beyond updates in clinical trials and guideline adoption, the RAD annual meeting also shines a spotlight on other clinically relevant aspects of care, such as management of skin of color, comorbidity management, and more.

For more information, check out the Revolutionizing Atopic Dermatitis (RAD) Annual Meeting website.